Fatal rhabdomyolysis in systemic lupus erythematosus.
Identifieur interne : 000386 ( PubMed/Corpus ); précédent : 000385; suivant : 000387Fatal rhabdomyolysis in systemic lupus erythematosus.
Auteurs : Jozélio Freire De Carvalho ; Licia Maria Henrique Da Mota ; Eloisa BonfaSource :
- Rheumatology international [ 1437-160X ] ; 2011.
English descriptors
- KwdEn :
- Acute Kidney Injury (diagnosis), Adult, Anti-Bacterial Agents (therapeutic use), Antibodies, Antinuclear (blood), Arthritis (diagnosis), Arthritis (drug therapy), Azathioprine (therapeutic use), Chloroquine (therapeutic use), Creatine Kinase (blood), Drug Therapy, Combination, Fatal Outcome, Female, Humans, Immunosuppressive Agents (therapeutic use), Leukopenia (diagnosis), Leukopenia (drug therapy), Lung Diseases (drug therapy), Lung Diseases (therapy), Lupus Erythematosus, Systemic (complications), Lupus Erythematosus, Systemic (drug therapy), Lupus Erythematosus, Systemic (pathology), Oral Ulcer (diagnosis), Oral Ulcer (drug therapy), Photosensitivity Disorders (diagnosis), Photosensitivity Disorders (drug therapy), Prednisone (therapeutic use), Respiration, Artificial, Rhabdomyolysis (diagnosis), Rhabdomyolysis (etiology), Rhabdomyolysis (pathology), Vasculitis (diagnosis), Vasculitis (drug therapy).
- MESH :
- chemical , blood : Antibodies, Antinuclear, Creatine Kinase.
- chemical , therapeutic use : Anti-Bacterial Agents, Azathioprine, Chloroquine, Immunosuppressive Agents, Prednisone.
- complications : Lupus Erythematosus, Systemic.
- diagnosis : Acute Kidney Injury, Arthritis, Leukopenia, Oral Ulcer, Photosensitivity Disorders, Rhabdomyolysis, Vasculitis.
- drug therapy : Arthritis, Leukopenia, Lung Diseases, Lupus Erythematosus, Systemic, Oral Ulcer, Photosensitivity Disorders, Vasculitis.
- etiology : Rhabdomyolysis.
- pathology : Lupus Erythematosus, Systemic, Rhabdomyolysis.
- therapy : Lung Diseases.
- Adult, Drug Therapy, Combination, Fatal Outcome, Female, Humans, Respiration, Artificial.
Abstract
The authors describe herein the sixth lupus case that evolved with rhabdomyolysis. A 36-year-old woman with systemic lupus erythematosus was admitted to our hospital with malaise, myalgia, dysphagia, fever, preserved muscle strength, leukocytosis (15,600 cells), and increased creatine kinase of 1,358 IU/L that reached 75,000 IU/L in few days. She denied the use of myotoxic drugs and alcohol. Urine 1 showed false positive for hemoglobinuria (myoglobin) without erythrocytes in the sediment, confirming the diagnosis of rhabdomyolysis. Secondary causes were excluded. She was treated with hyperhydration and alkalinization of urine. Despite treatment, the patient developed pulmonary congestion and she died. The authors also review in this article rhabdomyolysis in patients with systemic lupus erythematosus.
DOI: 10.1007/s00296-010-1674-0
PubMed: 21127876
Links to Exploration step
pubmed:21127876Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Fatal rhabdomyolysis in systemic lupus erythematosus.</title><author><name sortKey="De Carvalho, Jozelio Freire" sort="De Carvalho, Jozelio Freire" uniqKey="De Carvalho J" first="Jozélio Freire" last="De Carvalho">Jozélio Freire De Carvalho</name><affiliation><nlm:affiliation>Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Cerqueira César, São Paulo, SP, 01246-903, Brazil. jotafc@gmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Da Mota, Licia Maria Henrique" sort="Da Mota, Licia Maria Henrique" uniqKey="Da Mota L" first="Licia Maria Henrique" last="Da Mota">Licia Maria Henrique Da Mota</name></author><author><name sortKey="Bonfa, Eloisa" sort="Bonfa, Eloisa" uniqKey="Bonfa E" first="Eloisa" last="Bonfa">Eloisa Bonfa</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21127876</idno><idno type="pmid">21127876</idno><idno type="doi">10.1007/s00296-010-1674-0</idno><idno type="wicri:Area/PubMed/Corpus">000386</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000386</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Fatal rhabdomyolysis in systemic lupus erythematosus.</title><author><name sortKey="De Carvalho, Jozelio Freire" sort="De Carvalho, Jozelio Freire" uniqKey="De Carvalho J" first="Jozélio Freire" last="De Carvalho">Jozélio Freire De Carvalho</name><affiliation><nlm:affiliation>Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Cerqueira César, São Paulo, SP, 01246-903, Brazil. jotafc@gmail.com</nlm:affiliation></affiliation></author><author><name sortKey="Da Mota, Licia Maria Henrique" sort="Da Mota, Licia Maria Henrique" uniqKey="Da Mota L" first="Licia Maria Henrique" last="Da Mota">Licia Maria Henrique Da Mota</name></author><author><name sortKey="Bonfa, Eloisa" sort="Bonfa, Eloisa" uniqKey="Bonfa E" first="Eloisa" last="Bonfa">Eloisa Bonfa</name></author></analytic><series><title level="j">Rheumatology international</title><idno type="eISSN">1437-160X</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acute Kidney Injury (diagnosis)</term><term>Adult</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antibodies, Antinuclear (blood)</term><term>Arthritis (diagnosis)</term><term>Arthritis (drug therapy)</term><term>Azathioprine (therapeutic use)</term><term>Chloroquine (therapeutic use)</term><term>Creatine Kinase (blood)</term><term>Drug Therapy, Combination</term><term>Fatal Outcome</term><term>Female</term><term>Humans</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Leukopenia (diagnosis)</term><term>Leukopenia (drug therapy)</term><term>Lung Diseases (drug therapy)</term><term>Lung Diseases (therapy)</term><term>Lupus Erythematosus, Systemic (complications)</term><term>Lupus Erythematosus, Systemic (drug therapy)</term><term>Lupus Erythematosus, Systemic (pathology)</term><term>Oral Ulcer (diagnosis)</term><term>Oral Ulcer (drug therapy)</term><term>Photosensitivity Disorders (diagnosis)</term><term>Photosensitivity Disorders (drug therapy)</term><term>Prednisone (therapeutic use)</term><term>Respiration, Artificial</term><term>Rhabdomyolysis (diagnosis)</term><term>Rhabdomyolysis (etiology)</term><term>Rhabdomyolysis (pathology)</term><term>Vasculitis (diagnosis)</term><term>Vasculitis (drug therapy)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Antinuclear</term><term>Creatine Kinase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Azathioprine</term><term>Chloroquine</term><term>Immunosuppressive Agents</term><term>Prednisone</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Lupus Erythematosus, Systemic</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Acute Kidney Injury</term><term>Arthritis</term><term>Leukopenia</term><term>Oral Ulcer</term><term>Photosensitivity Disorders</term><term>Rhabdomyolysis</term><term>Vasculitis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis</term><term>Leukopenia</term><term>Lung Diseases</term><term>Lupus Erythematosus, Systemic</term><term>Oral Ulcer</term><term>Photosensitivity Disorders</term><term>Vasculitis</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Rhabdomyolysis</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Lupus Erythematosus, Systemic</term><term>Rhabdomyolysis</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Lung Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Therapy, Combination</term><term>Fatal Outcome</term><term>Female</term><term>Humans</term><term>Respiration, Artificial</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The authors describe herein the sixth lupus case that evolved with rhabdomyolysis. A 36-year-old woman with systemic lupus erythematosus was admitted to our hospital with malaise, myalgia, dysphagia, fever, preserved muscle strength, leukocytosis (15,600 cells), and increased creatine kinase of 1,358 IU/L that reached 75,000 IU/L in few days. She denied the use of myotoxic drugs and alcohol. Urine 1 showed false positive for hemoglobinuria (myoglobin) without erythrocytes in the sediment, confirming the diagnosis of rhabdomyolysis. Secondary causes were excluded. She was treated with hyperhydration and alkalinization of urine. Despite treatment, the patient developed pulmonary congestion and she died. The authors also review in this article rhabdomyolysis in patients with systemic lupus erythematosus.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21127876</PMID><DateCompleted><Year>2012</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>9</Issue><PubDate><Year>2011</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol. Int.</ISOAbbreviation></Journal><ArticleTitle>Fatal rhabdomyolysis in systemic lupus erythematosus.</ArticleTitle><Pagination><MedlinePgn>1243-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-010-1674-0</ELocationID><Abstract><AbstractText>The authors describe herein the sixth lupus case that evolved with rhabdomyolysis. A 36-year-old woman with systemic lupus erythematosus was admitted to our hospital with malaise, myalgia, dysphagia, fever, preserved muscle strength, leukocytosis (15,600 cells), and increased creatine kinase of 1,358 IU/L that reached 75,000 IU/L in few days. She denied the use of myotoxic drugs and alcohol. Urine 1 showed false positive for hemoglobinuria (myoglobin) without erythrocytes in the sediment, confirming the diagnosis of rhabdomyolysis. Secondary causes were excluded. She was treated with hyperhydration and alkalinization of urine. Despite treatment, the patient developed pulmonary congestion and she died. The authors also review in this article rhabdomyolysis in patients with systemic lupus erythematosus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Jozélio Freire</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Cerqueira César, São Paulo, SP, 01246-903, Brazil. jotafc@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>da Mota</LastName><ForeName>Licia Maria Henrique</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Bonfa</LastName><ForeName>Eloisa</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>886U3H6UFF</RegistryNumber><NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.3.2</RegistryNumber><NameOfSubstance UI="D003402">Creatine Kinase</NameOfSubstance></Chemical><Chemical><RegistryNumber>MRK240IY2L</RegistryNumber><NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D058186" MajorTopicYN="N">Acute Kidney Injury</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001168" MajorTopicYN="N">Arthritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003402" MajorTopicYN="N">Creatine Kinase</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017809" MajorTopicYN="N">Fatal Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007970" MajorTopicYN="N">Leukopenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008171" MajorTopicYN="N">Lung Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="N">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019226" MajorTopicYN="N">Oral Ulcer</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010787" MajorTopicYN="N">Photosensitivity Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012206" MajorTopicYN="N">Rhabdomyolysis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014657" MajorTopicYN="N">Vasculitis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21127876</ArticleId><ArticleId IdType="doi">10.1007/s00296-010-1674-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ann Pharmacother. 1999 Nov;33(11):1176-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10573315</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Intern Med. 2008 Dec;19(8):568-74</Citation><ArticleIdList><ArticleId IdType="pubmed">19046720</ArticleId></ArticleIdList></Reference><Reference><Citation>Immun Infekt. 1991 Apr;19(2):58-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1855812</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care. 2005 Apr;9(2):158-69</Citation><ArticleIdList><ArticleId IdType="pubmed">15774072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Drugs Dermatol. 2005 Mar-Apr;4(2):225-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15776783</ArticleId></ArticleIdList></Reference><Reference><Citation>J Rheumatol. 1994 Oct;21(10):1967-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7837170</ArticleId></ArticleIdList></Reference><Reference><Citation>Intern Emerg Med. 2007 Oct;2(3):210-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17909702</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheumatology (Oxford). 2000 Jan;39(1):110-2</Citation><ArticleIdList><ArticleId IdType="pubmed">10662885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Indian Acad Neurol. 2009 Jan;12(1):45-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20151010</ArticleId></ArticleIdList></Reference><Reference><Citation>Neth J Med. 2009 Oct;67(9):272-83</Citation><ArticleIdList><ArticleId IdType="pubmed">19841484</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Artif Organs. 2004 Dec;27(12):1030-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15645612</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000386 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000386 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:21127876
|texte= Fatal rhabdomyolysis in systemic lupus erythematosus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:21127876" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |